The inhibition of UDP-glucuronosyltransferases (UGTs) by vitamin A

References

• Ahmed F. (1999). Vitamin A deficiency in Bangladesh: a review and recommendations for improvement. Public Health Nutr 2:1–14.
   PubMed Web of Science ®Google Scholar
• de Oliveira MR. (2015a). The neurotoxic effects of vitamin A and retinoids. An Acad Bras Cienc 87:1361–73.
   PubMed Web of Science ®Google Scholar
• de Oliveira MR. (2015b). Vitamin A and retinoids as mitochondrial toxicants. Oxid Med Cell Longev 2015:140267.
   PubMed Web of Science ®Google Scholar
• Fang ZZ, He RR, Cao YF, et al. (2013). A model of in vitro UDP-glucuronosyltransferase inhibition by bile acids predicts possible metabolic disorders. J Lipid Res 54:3334–44.
   PubMed Web of Science ®Google Scholar
• Gao X, Qu H, Ai CZ, et al. (2015). Regulation profile of phosphatidylcholines (PCs) and lysophosphatidylcholines (LPCs) components towards UDP-glucuronosyltransferases (UGTs) isoforms. Xenobiotica 45:197–206.
   PubMed Web of Science ®Google Scholar
• Haberkorn V, Heydel JM, Mounie J, et al. (2001). Influence of vitamin A status on the regulation of uridine (5′-)diphosphate-glucuronosyltransferase (UGT) 1A1 and UGT1A6 expression by L-triiodothyronine. Br J Nutr 85:289–97.
   PubMed Web of Science ®Google Scholar
• Haberkorn V, Heydel JM, Mounie J, et al. (2002). Vitamin A modulates the effects of thyroid hormone on UDP-glucuronosyltransferase expression and activity in rat liver. Mol Cell Endocrinol 190:167–75.
   PubMed Web of Science ®Google Scholar
• House L, Ramirez J, Seminerio M, et al. (2015). In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7. Xenobiotica 45:990–8.
   PubMed Web of Science ®Google Scholar
• Ito K, Brown HS, Houston JB. (2004). Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473–86.
   PubMed Web of Science ®Google Scholar
• Lu Y, Bratton S, Heydel JM, Radominska-Pandya A. (2008). Effect of retinoids on UDP-glucuronosyltransferase 2B7 mRNA expression in Caco-2 cells. Drug Metab Pharmacokinet 23:364–72.
   PubMed Web of Science ®Google Scholar
• Mactier H, Weaver LT. (2005). Vitamin A and preterm infants: what we know, what we don't know, and what we need to know. Arch Dis Child Fetal Neonatal Ed 290:F103–8.
   Web of Science ®Google Scholar
• Miley MJ, Zielinska AK, Keenan JE, et al. (2007). Crystal structure of the cofactor-binding domain of the human phase II drug-metabolism enzyme UDP-glucuronosyltransferase 2B7. J Mol Biol 369:498–511.
   PubMed Web of Science ®Google Scholar
• Myhre AM, Carlsen MH, Bohn SK, et al. (2003). Water-miscible, emulsified, and solid forms of retinol supplements are more toxic than oil-based preparations. Am J Clin Nutr 78:1152–9.
   PubMed Web of Science ®Google Scholar
• Oda S, Fukami T, Yokoi T, Nakajima M. (2015). A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30:30–51.
   PubMed Web of Science ®Google Scholar
• Ouzzine M, Gulberti S, Ramalanjaona N, et al. (2014). The UDP-glucuronosyltransferases of the blood-brain barrier: their role in drug metabolism and detoxication. Front Cell Neurosci 8:349.
   PubMed Web of Science ®Google Scholar
• Pattanawongsa A, Nair PC, Rowland A, Miners JO. (2016). Human UDP-glucuronosyltransferase (UGT) 2B10: validation of cotinine as a selective probe substrate, inhibition by ugt enzyme-selective inhibitors and antidepressant and antipsychotic drugs, and structural determinants of enzyme inhibition. Drug Metab Dispos 44:378–88.
   PubMed Web of Science ®Google Scholar
• Peer CJ, Sissung TM, Kim A, et al. (2012). Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res 18:2099–107.
   PubMed Web of Science ®Google Scholar
• Rowbotham SE, Illingworth NA, Daly AK, et al. (2010). Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug Metab Dispos 38:1211–17.
   PubMed Web of Science ®Google Scholar
• Saadeddin A, Torres-Molina F, Carcel-Trullols J, et al. (2004). Pharmacokinetics of the time-dependent elimination of all-trans-retinoic acid in rats. AAPS J 6:1–9.
   PubMed Web of Science ®Google Scholar
• Samokyszyn VM, Gall WE, Zawada G, et al. (2000). 4-Hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. J Biol Chem 275:6908–14.
   PubMed Web of Science ®Google Scholar
• Thorne-Lyman A, Fawzi WW. (2012). Vitamin A supplementation, infectious disease and child mortality: a summary of the evidence. Nestle Nutr Inst Workshop Ser 70:79–90.
   PubMedGoogle Scholar
• Tripathi SP, Bhadauriya A, Patil A, Sangamwar AT. (2013). Substrate selectivity of human intestinal UDP-glucuronosyltransferases (UGTs): in silico and in vitro insights. Drug Metab Rev 45:231–52.
   PubMed Web of Science ®Google Scholar
• Tsoutsikos P, Miners JO, Stapleton A, et al. (2004). Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191–9.
   PubMed Web of Science ®Google Scholar
• Uchaipichat V, Mackenzie PI, Elliot DJ, Miners JO. (2006). Selectivity of substrate (trifluoperazine) and inhibitor (amitriptyline, androsterone, canrenoic acid, hecogenin, phenylbutazone, quinidine, quinine, and sulfinpyrazone) “for human udp-glucuronosyltransferases” for human. Drug Metab Dispos 34:449–56.
   PubMed Web of Science ®Google Scholar
• Uray IP, Dmitrovsky E, Brown PH. (2016). Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Semin Oncol 43:49–64.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Cao YF, Ran RX, et al. (2016). Strong specific inhibition of UDP-glucuronosyltransferase 2B7 by atractylenolide I and III. Phytother Res 30:25–30.
   PubMed Web of Science ®Google Scholar
• Zhu L, Xiao L, Li W, et al. (2016). Human UDP-glucuronosyltransferases 1A1, 1A3, 1A9, 2B4 and 2B7 are inhibited by diethylstilbesterol. Basic Clin Pharmacol Toxicol. [Epub ahead of print]. doi: 10.1111/bcpt.12618.
   Web of Science ®Google Scholar
• Zucker SD, Qin X, Rouster SD, et al. (2001). Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 98:12671–6.
   PubMed Web of Science ®Google Scholar